Skip to content

Intermittent Fasting for the Treatment of Type 2 Diabetes Mellitus

Intermittent Fasting for the Treatment of Type 2 Diabetes Mellitus

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05860413
Enrollment
57
Registered
2023-05-16
Start date
2023-01-24
Completion date
2025-05-20
Last updated
2025-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Brief summary

To test whether a lifestyle program featuring one of two forms of intermittent fasting (IER or TRE) can feasibly and effectively improve glycemia in patients with type 2 diabetes, and potentially induce diabetes remission.

Detailed description

Intermittent energy restriction (IER) and time-restricted eating (TRE) are two distinct forms of intermittent fasting which have yet to be compared for the treatment of type 2 diabetes. Investigators will test whether a comprehensive, intensive lifestyle program featuring each of these intermittent fasting approaches is feasible and effective for improving glycemic control in patients diagnosed with type 2 diabetes within the past 10 years. Both interventions will be delivered over one year in three phases: (1) a 12-week weight loss program featuring weekly group meetings, (2) a 12-week weight maintenance program featuring biweekly group meetings, and (3) a 6-month low-contact follow up period featuring monthly check-ins.

Interventions

During Phase 1 (Weight Loss), participants will follow a very-low energy diet (VLED; 550-800 kcal/d) 2-3 days per week. On other days, participants do not have a specific kcal goal (non-fasting days). After Phase 1, IER participants will be instructed to follow a VLED 1-2 days per week as needed for weight maintenance.

Participants will eat within an 8-hour period most days (at least 5 days per week). All foods and beverages containing calories will be restricted to this 8-hour period but calorie-free beverages (coffee, tea, diet soda, etc.) are allowed at any time. TRE participants will follow healthy eating guidelines for weight loss during Phase 1 but not follow a specific kcal prescription or restrict intake thereafter.

Sponsors

American Diabetes Association
CollaboratorOTHER
University of Kansas Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
21 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. Diagnosed with type 2 diabetes in the past 10 years. 2. Age 21-65 years 3. BMI of 25 - 45 kg/m2 4. HbA1c of 6.7-9.5%, or those with A1c of \<6.7% on glucose-lowering medications 5. Ability to participate in a graduated physical activity program 6. Clearance from study physician.

Exclusion criteria

1. Inability to attend health education meetings. 2. Weight change of \>=5% in the previous 3 months. 3. Addition of new antihyperglycemic or weight-reducing medication in the previous 2 months. 4. Serious medical risk such as ongoing treatment for cancer, uncontrolled hypertension, recent cardiac event, or other medical condition presenting acute risk of participation in a lifestyle change program. 5. Untreated depression or anxiety, or increase in associated medications in the previous 3 months. 6. Current participation in another lifestyle change intervention, such as a tobacco cessation program or physical activity program. 7. Pregnancy or lactation within the previous six months 8. Weight of \>450 lbs 9. Currently taking medications that may result in hypoglycemia during fasting and unwilling to stop prior to the study

Design outcomes

Primary

MeasureTime frameDescription
Retention52 weeksFeasibility of IER and TRE over one year assessed by retention (# completed / # enrolled) and attendance (# classes attended / # classes offered).
Adherence to diet protocolsWeekly from baseline to 52 weeksAcceptability of IER and TRE over one year as assessed by compliance to program recommendations (# weeks adhered / # study weeks).

Secondary

MeasureTime frameDescription
HbA1cChange from baseline to 24 weeksEstimate the effects for both IER and TRE on long-term glycemic control assessed via HbA1c
Oral Glucose Tolerance TestChange from baseline to 24 weeksEstimate the effects for both IER and TRE on fasting and 3 hr glucose result.
Isulin resistanceChange from baseline to 24 weeksEstimate the effects for both IER and TRE on insulin resistance estimated by the oral minimal model during a mixed meal tolerance test
Insulin sensitivityChange from baseline to 24 weeksEstimate the effects for both IER and TRE on insulin sensitivity estimated by the oral minimal model during a mixed meal tolerance test

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026